Hypoparathyroidism: Similarities and differences between Western and Eastern countries.

Yu-Ying Yang, Claus-Christian Glüer, Jian-Min Liu, Lars Rejnmark, Peter Pietschmann, Salvatore Minisola, Ling Wang, Yan-Hua Deng, Li-Hao Sun, Aliya A Khan

Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2025;36(3):391-402

PMID: 39777494

Full Text on Springer View on PubMed

Abstract

BACKGROUD

Hypoparathyroidism (hypoPT) is characterized by acute and chronic complications due to insufficient parathyroid hormone (PTH) production or action. Several management guidelines have been developed, but mostly based on evidence from Western countries. Data from Eastern countries have not been systematically compared with those from Western countries.

METHODS

Literatures regarding to the epidemiology, genetics, risk factors, clinical manifestations and therapies for hypoPT in Easten and Western countries, including China, South Korea, Japan, India, and USA, Canada, Italy, and etc., were searched through PubMed and CNKI. This review was officially endorsed by European Calcified Tissue Society (ECTS) board.

RESULTS

Postoperative hypoPT is the major form of hypoPT in both Western and Eastern countries. The genetic profiles and clinical features of hypoPT are similar in Eastern and Western countries. The most commonly used medications in Eastern countries are calcium and native vitamin D or active vitamin D analogues, similar to their Western counterparts. While PTH replacement therapy is not available and approved to use in most Eastern countries.

CONCLUSION

Physicians and surgeons should follow the guidelines on the management of thyroid nodules, taking more care of protecting parathyroid glands during surgery. The cross-talk between East and West in the management of hypoPT should be continued. Direct comparisons of the management strategies in patients with hypoPT between Eastern and Wester countries regarding to the morbidity, mortality, quality of life, optimal dosage, efficacies and side-effects of conventional therapies or newer medications, as well as pharmacogenetics and pharmacoeconomics, would be valuable.

Address: Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.; National Clinical Research Center for Metabolic Diseases (Shanghai), Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai National Center for Translational Medicine, Shanghai, China.; Department of Endocrinology and Internal Medicine, Aarhus University Hospital, 8200, Aarhus N, Denmark.; Department of Radiology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China.; Division of Cellular and Molecular Pathophysiology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.; Section Biomedical Imaging, Department of Radiology and Neuroradiology, North Competence Center, University Medical Center Schleswig-Holstein Kiel, Kiel University, Molecular Imaging, Kiel, Germany.; Divisions of Endocrinology and Metabolism and Geriatrics, McMaster University, Hamilton, ON, L8S 4L8, Canada. [email protected].; Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy. [email protected].; Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [email protected].; National Clinical Research Center for Metabolic Diseases (Shanghai), Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai National Center for Translational Medicine, Shanghai, China. [email protected].

DOI: 10.1007/s00198-024-07352-6

Link outs

Subscription / membership required

Full Text Sources:

https://doi.org/10.1007/s00198-024-07352-6

MeSH Terms: Humans, Hypoparathyroidism, Parathyroid Hormone, Risk Factors, Vitamin D, Hormone Replacement Therapy, Western World